Allena Stock Analysis

ALNA -  USA Stock  

USD 0.38  0.02  5.00%

The big decline in price over the last few months for Allena Pharmaceuticals could raise concerns from investors as the firm it trading at a share price of 0.38 on 2,158,900 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Allena Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.17. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Allena Pharmaceuticals partners.
Please continue to Trending Equities.

Allena Stock Analysis 

 
Refresh
The Allena Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Allena Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Allena Stock analysis module also helps to analyze the Allena Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Allena Stock Analysis Notes

About 24.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.37. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allena Pharmaceuticals recorded a loss per share of 0.84. The entity had not issued any dividends in recent years. Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts. Allena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 35 people. For more info on Allena Pharmaceuticals please contact Alexey Margolin at 617 467 4577 or go to https://www.allenapharma.com.

Allena Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Allena Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Allena Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Allena Pharmaceuticals generated a negative expected return over the last 90 days
Allena Pharmaceuticals has high historical volatility and very poor performance
Allena Pharmaceuticals has some characteristics of a very speculative penny stock
Allena Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (48.56 M).
Allena Pharmaceuticals currently holds about 40.42 M in cash with (40.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Allena Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Latest headline from www.investorsobserver.com: Wall Street Set for Positive Open, Data Eyed - InvestorsObserver

Allena Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Allena Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Allena Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of March 2022
Next Earnings Report10th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Allena Largest EPS Surprises

Earnings surprises can significantly impact Allena Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-10
2021-06-30-0.2-0.24-0.0420 
2021-03-09
2020-12-31-0.185-0.24-0.05529 
2018-03-27
2017-12-31-0.5375-0.480.057510 
View All Earnings Estimates

Allena Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Allena Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Allena Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Allena Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
4th of January 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
23rd of December 2021
Financial Statements and Exhibits. Other Events. Termination of a Material Definitive Agreement. Entry into a Material Definitive Agreement
View
10th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
29th of September 2021
Financial Statements and Exhibits. Other Events
View
27th of August 2021
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
10th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of July 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
View
13th of July 2021
Financial Statements and Exhibits. Other Events
View

Allena Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Allena Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allena Pharmaceuticals backward and forwards among themselves. Allena Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Allena Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Spire Wealth ManagementCommon Shares91.9 K54 K
Aigh Capital Management LlcCommon SharesM3.6 M
Frazier Management LlcCommon Shares3.3 MM
Trv Gp Ii LlcCommon Shares2.8 M2.5 M
Fmr LlcCommon Shares2.3 M2.1 M
Vanguard Group IncCommon SharesM1.8 M
Altium Capital Management LpCommon Shares1.1 M963 K
Note, although Allena Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Allena Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 38.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allena Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Allena Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Allena Profitablity

Allena Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Allena Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Allena Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Allena Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Allena Pharmaceuticals' profitability requires more research than a typical breakdown of Allena Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.96) (1.03) 
Return on Average Equity(1.69) (1.83) 
Return on Invested Capital(4.65) (5.02) 

Management Efficiency

The entity has return on total asset (ROA) of (78.31) % which means that it has lost $78.31 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (219.67) %, meaning that it created substantial loss on money invested by shareholders. Allena Pharmaceuticals management efficiency ratios could be used to measure how well allena pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of January 23, 2022, Return on Average Assets is expected to decline to -1.03. In addition to that, Return on Average Equity is expected to decline to -1.83. Allena Pharmaceuticals Total Assets are projected to decrease significantly based on the last few years of reporting. The past year's Total Assets were at 35.04 Million. The current year Current Assets is expected to grow to about 42.2 M, whereas Return on Average Assets are forecasted to decline to (1.03) .
Last ReportedProjected for 2022
Book Value per Share 0.80  0.86 
Enterprise Value over EBIT(1.15) (1.24) 
Enterprise Value over EBITDA(1.05) (1.14) 
Price to Book Value 2.50  2.86 
Tangible Assets Book Value per Share 1.08  1.11 
Enterprise Value26 M26.7 M
Tangible Asset Value35 M43.3 M

Technical Drivers

As of the 23rd of January, Allena Pharmaceuticals shows the risk adjusted performance of (0.18), and Mean Deviation of 3.64. Allena Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Allena Pharmaceuticals, which can be compared to its rivals. Please confirm Allena Pharmaceuticals variance and the relationship between the treynor ratio and expected short fall to decide if Allena Pharmaceuticals is priced correctly, providing market reflects its regular price of 0.38 per share. As Allena Pharmaceuticals appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Allena Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Allena Pharmaceuticals more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Allena Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allena Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allena Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allena Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Louis Brenner over two months ago via Macroaxis 
Exercise or conversion by Louis Brenner of 125582 shares of Allena Pharmaceuticals subject to Rule 16b-3
Louis Brenner over two months ago via Macroaxis 
Exercise or conversion by Louis Brenner of 125582 shares of Allena Pharmaceuticals subject to Rule 16b-3
James Topper over two months ago via Macroaxis 
Conversion by James Topper of 4629630 shares of Allena Pharmaceuticals
Allene Diaz over six months ago via Macroaxis 
Acquisition by Allene Diaz of 37000 shares of Allena Pharmaceuticals subject to Rule 16b-3
Louis Brenner over six months ago via Macroaxis 
Exercise or conversion by Louis Brenner of 83721 shares of Allena Pharmaceuticals subject to Rule 16b-3
Fitzpatrick Mark J over six months ago via Macroaxis 
Acquisition by Fitzpatrick Mark J of 74000 shares of Allena Pharmaceuticals subject to Rule 16b-3
Louis Brenner over six months ago via Macroaxis 
Acquisition by Louis Brenner of 886400 shares of Allena Pharmaceuticals subject to Rule 16b-3
Katz Richard D over six months ago via Macroaxis 
Acquisition by Katz Richard D of 400000 shares of Allena Pharmaceuticals subject to Rule 16b-3
Edward Wholihan over a year ago via Macroaxis 
Exercise or conversion by Edward Wholihan of 164822 shares of Allena Pharmaceuticals subject to Rule 16b-3
Louis Brenner over a year ago via Macroaxis 
Acquisition by Louis Brenner of 209303 shares of Allena Pharmaceuticals subject to Rule 16b-3
Allene Diaz over a year ago via Macroaxis 
Acquisition by Allene Diaz of 14000 shares of Allena Pharmaceuticals subject to Rule 16b-3
Miller Ann Calby over a year ago via Macroaxis 
Acquisition by Miller Ann Calby of 28000 shares of Allena Pharmaceuticals subject to Rule 16b-3

Allena Pharmaceuticals Predictive Daily Indicators

Allena Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Allena Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Allena Pharmaceuticals Forecast Models

Allena Pharmaceuticals time-series forecasting models is one of many Allena Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Allena Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Allena Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Allena Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Allena shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Allena Pharmaceuticals. By using and applying Allena Stock analysis, traders can create a robust methodology for identifying Allena entry and exit points for their positions.
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts. Allena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 35 people.

Current Allena Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Allena analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Allena analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.06Strong Buy4Odds
Allena Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Allena analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Allena stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Allena Pharmaceuticals, talking to its executives and customers, or listening to Allena conference calls.
Allena Analyst Advice Details

Allena Stock Analysis Indicators

Allena Pharmaceuticals stock analysis indicators help investors evaluate how Allena Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Allena Pharmaceuticals shares will generate the highest return on investment. By understating and applying Allena Pharmaceuticals stock analysis, traders can identify Allena Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio5.27
Fifty Two Week Low0.4270
Shares Short Prior Month3.21M
Average Daily Volume Last 10 Day6.09M
Average Daily Volume In Three Month4.06M
Shares Percent Shares Out3.49%
Short Percent Of Float3.66%
Forward Price Earnings-0.66
Float Shares81.45M
Fifty Two Week High2.7800
Enterprise Value To Ebitda-0.38
Fifty Day Average0.6822
Two Hundred Day Average0.9636
Please continue to Trending Equities. Note that the Allena Pharmaceuticals information on this page should be used as a complementary analysis to other Allena Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Allena Stock analysis

When running Allena Pharmaceuticals price analysis, check to measure Allena Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allena Pharmaceuticals is operating at the current time. Most of Allena Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Allena Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allena Pharmaceuticals' price. Additionally, you may evaluate how the addition of Allena Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Allena Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allena Pharmaceuticals. If investors know Allena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allena Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allena Pharmaceuticals is measured differently than its book value, which is the value of Allena that is recorded on the company's balance sheet. Investors also form their own opinion of Allena Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Allena Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allena Pharmaceuticals' market value can be influenced by many factors that don't directly affect Allena Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allena Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Allena Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allena Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.